Manufacturer of Controlled Substances; Notice of Application, 46921 [E6-13325]

Download as PDF Federal Register / Vol. 71, No. 157 / Tuesday, August 15, 2006 / Notices meet to fulfill its mission to manage, develop, and protect water and related resources in an environmentally and economically sound manner in the interest of the American public. This project will examine Reclamation’s core capabilities and the agency’s ability to respond to both expected and unforeseeable future needs in an innovative and timely manner. This project will result in essential changes in a number of key areas, which are outlined in, Managing for Excellence— An Action Plan for the 21st Century Bureau of Reclamation. For more information regarding the Project, Action Plan, and specific actions being taken, please visit the Managing for Excellence Web page at https:// www.usbr.gov/excellence. Registration Although you may register the first day of the conference starting at 7:30 a.m., we highly encourage you to register online at https://www.usbr.gov/ excellence, or by phone at 303–445– 2808. DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 27, 2006, Dade Behring Inc., 100 GBE Drive, MS514, Post Office Box 6101, Attention: RA/QS, Newark, Delaware 19714–6101, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in Schedules I and II: Schedule mstockstill on PROD1PC61 with NOTICES I II II The company plans to produce the listed controlled substances in bulk to be used in the manufacture of reagents and drug calibrator/controls for DEA exempt products. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance VerDate Aug<31>2005 15:41 Aug 14, 2006 Jkt 208001 BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Manufacturer of Controlled Substances; Notice of Application BILLING CODE 4310–MN–M Tetrahydrocannabinols (7370) ..... Ecgonine (9180) ........................... Morphine (9300) ........................... Dated: August 7, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–13325 Filed 8–14–06; 8:45 am] Drug Enforcement Administration Dated: August 3, 2006. William E. Rinne, Acting Commissioner, Washington Office. [FR Doc. 06–6931 Filed 8–14–06; 8:45 am] Drug may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 16, 2006. Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 27, 2006, Dade Behring, Inc., Regulatory Affairs, Quality Systems, 20400 Mariani Avenue, Cupertino, California 95014, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the basic classes of controlled substances listed in Schedule I and II: Drug Schedule Tetrahydrocannabinols (7370) ..... Benzoylecgonine (9180) ............... Morphine (9300) ........................... I II II The company plans to produce the listed controlled substances in bulk products to be used in the manufacture of reagents and drug calibrator/controls for DEA exempt products. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail may be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA PO 00000 Frm 00033 Fmt 4703 Sfmt 4703 46921 Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than October 16, 2006. Dated: August 7, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–13327 Filed 8–14–06; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated April 18, 2006 and published in the Federal Register on April 25, 2006 (71 FR 23949), Hospira, Inc., 1776 North Centennial Drive, McPherson, Kansas 67460–1247, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of Remifentanil (9739), a basic class of controlled substance listed in Schedule II. The company plans to import the basic class of controlled substance for use in dosage unit manufacturing. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Hospira, Inc. to import the basic class of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Hospira, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic class of controlled substances listed. Dated: August 7, 2006. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E6–13328 Filed 8–14–06; 8:45 am] BILLING CODE 4410–09–P E:\FR\FM\15AUN1.SGM 15AUN1

Agencies

[Federal Register Volume 71, Number 157 (Tuesday, August 15, 2006)]
[Notices]
[Page 46921]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E6-13325]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 27, 2006, Dade Behring 
Inc., 100 GBE Drive, MS514, Post Office Box 6101, Attention: RA/QS, 
Newark, Delaware 19714-6101, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of the basic classes of controlled substances listed in 
Schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Tetrahydrocannabinols (7370)...............  I
Ecgonine (9180)............................  II
Morphine (9300)............................  II
------------------------------------------------------------------------

    The company plans to produce the listed controlled substances in 
bulk to be used in the manufacture of reagents and drug calibrator/
controls for DEA exempt products.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative/ODL; or any being sent via express mail should be sent 
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must 
be filed no later than October 16, 2006.

    Dated: August 7, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E6-13325 Filed 8-14-06; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.